The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Seed - II | Alive

Total Raised




Last Raised

$330K | 6 yrs ago

About TAXA Biotechnologies

TAXA Biotechnologies, formerly growing plant, has been specifically designed to enable anyone to perform metabolic engineering of plants without stepping into a lab. We provide access to protein engineering, DNA assembly, transient experiments and stable transformation as a service. The best thing is that anything "Powered by TAXA" is designed to be free from expensive regulatory approval, meaning the products are available for sale or distribution to consumers in the United States immediately after they are developed. For a detailed list of the experiments which can be run on our platform please see the Services page.

TAXA Biotechnologies Headquarter Location

665 3rd Street Suite 230

San Francisco, California, 94107,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing TAXA Biotechnologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

TAXA Biotechnologies is included in 1 Expert Collection, including Synthetic Biology.


Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

Latest TAXA Biotechnologies News

TAXA Biotechnologies to Close Out Successful Regulation Crowdfunding Campaign on Wefunder: Company Raises $250,000+ to Scale Up Production of Its First Products

Aug 2, 2016

SAN FRANCISCO, CA--(Marketwired - Aug 2, 2016) - TAXA Biotechnologies , the first company to offer the genetic engineering of plants as a service, and Wefunder , the most popular platform for Regulation Crowdfunding, announced today that TAXA is one of the first companies that will close a successful Regulation Crowdfunding offering. The company met its $200,000 goal in about 10 weeks, via 400+ individual investors. Regulation Crowdfunding is a new option enabled by the recent passage of Title III of the JOBS Act, and allows everyday people (not just the wealthy) to make equity investments of as little as $100 in startups and small businesses. Wefunder, one of several FINRA-approved portals for these offerings, has become the clear leader in the space, hosting more than half of all Regulation Crowdfunding offerings. To date, Wefunder has helped its portfolio companies raise more than 6x the total of all the other portals combined. TAXA Biotechnologies enables cheaper, faster and better genetic engineering of plants. Its first product is a glowing plant, and the company is also close to shipping a fragrant moss. The company plans to use the proceeds from its Wefunder offering to scale up its production capabilities to deliver both of these products and offer genetic engineering of plants as a service to partners. TAXA founder and CEO Antony Evans said he decided to raise funds using Regulation Crowdfunding after a very successful traditional crowdfunding campaign. "We wanted to give our earlier crowdfunding supporters the opportunity to have equity in the company, and many of those people did come back and invest via Wefunder," said Evans. "This is a great, new fundraising model for startups, and we would absolutely come back and do it again. Wefunder made the process relatively easy for us, and their support and promotion of our offering was outstanding. " "We were excited to see TAXA's early Kickstarter backers also invest on Wefunder," said Wefunder co-founder and CEO Nick Tommarello. "The success of the TAXA offering demonstrates that everyday Americans also want to invest in early-stage startups solving hard technical challenges. " To register as a potential investor and review investment opportunities at Wefunder, visit . The minimum investment is $100. To get funded on Wefunder, visit . About Wefunder Wefunder helps anyone invest as little as $100 in startups you love, and is the most popular platform for Regulation Crowdfunding. Its vision is to build a new type of stock market ("a NASDAQ for riskier ventures") that lets the public allocate capital to a wider range of businesses, more broadly and efficiently than banks or venture capitalists. Investors on Wefunder have invested more than $20 million into 130+ companies since 2013, including Zenefits, Checkr and Casetext. Learn more about Wefunder's story at or follow us @wefunder . About TAXA Biotechnologies TAXA Biotechnologies was founded in 2013 and has its principal office in San Francisco, California. TAXA Biotechnologies is a company of biologists and experts who use synthetic biology technologies to engineer new organisms which can be nurtured at home as carbon-positive alternatives to existing products. The first biotech investment by Y Combinator, TAXA Biotechnologies provides access to a platform for protein engineering, automated DNA assembly, transient experiments and stable transformation as a service that is already being used by three partners. Contact Information

TAXA Biotechnologies Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

TAXA Biotechnologies Rank

  • When was TAXA Biotechnologies founded?

    TAXA Biotechnologies was founded in 2013.

  • Where is TAXA Biotechnologies's headquarters?

    TAXA Biotechnologies's headquarters is located at 665 3rd Street, San Francisco.

  • What is TAXA Biotechnologies's latest funding round?

    TAXA Biotechnologies's latest funding round is Seed - II.

  • How much did TAXA Biotechnologies raise?

    TAXA Biotechnologies raised a total of $1.26M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.